Samsung Bioepis Achieves Record Sales of 1.672 Trillion Won Last Year

Samsung Bioepis achieved its highest performance last year in terms of sales. Excluding short-term milestone revenues, operating profit also doubled, showing strong results.

Samsung Epirus Holdings announced on the 26th that it recorded annual sales of 1.672 trillion won and operating profit of 375.9 billion won last year.

Last year, sales excluding milestones amounted to 1.6269 trillion won, an increase of 360.1 billion won (28%) compared to the previous year (1.2668 trillion won). Milestones are one-time revenues that come from technology transfer contracts and do not recur every time.

Last year, operating profit excluding milestones was 330.8 billion won, an increase of 166.3 billion won (101%) compared to the previous year (164.5 billion won). Including milestones, last year's operating profit was 375.9 billion won, a decrease of 14% (59.5 billion won) compared to the previous year (435.4 billion won).

Samsung Bioepis is expanding its market in the United States, the world's largest pharmaceutical market, through collaboration with local marketing partners and supply channels with pharmacy benefit managers (PBM). Last year, it launched biosimilars for the treatment of immune diseases, Stelara and Soliris, in the U.S. market. In particular, the Stelara biosimilar has secured a stable sales channel by signing a 'private label' contract with a large PBM that supplies drugs under its own brand, along with partnerships.

In Europe, which accounts for more than 60% of total sales, collaboration with partners and direct sales are ongoing. It has increased the number of products sold to 10, ten years after launching its first product, the biosimilar for the treatment of inflammatory joint disease, Enbrel (SB4), in 2016. Among these, four products (Soliris, Prolia, Xgeva, Lucentis biosimilars) are being sold directly through local sales networks.